Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Redx Pharma Opens £10.5 Million R&D Centre in UK

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Liverpool-based drug discovery and development company Redx Pharma is to open a new research and development facility at AZ's Alderley Park site in Cheshire.

The new venture, Redx Anti-Infectives Ltd, will create 119 high value science jobs at the site, establishing a new team to develop drugs combatting resistance to antibiotics and new medicines to tackle viral infections. A particular focus will be hard to treat infections. These include the growing threat of drug resistant superbugs like MRSA, as well as conditions such as influenza, Hepatitis C and HIV. A further 28 specialist jobs are expected to be created within the wider supply chain.

Redx Anti-Infectives began operations at the end of April 2013 supported by a grant of £4.7 million from the UK Government's Regional Growth Fund (RGF). The company has recently completed a significant funding round, brokered by Manchester-based Acceleris Corporate Finance. A combination of commercial partnering revenue and shareholder equity is also funding Redx Anti-Infectives.

Dr Neil Murray, chief executive of Redx Pharma, commented: The World Health Organisation has identified drug resistance, particularly in the area of antibiotics, as one of the most pressing human health concerns globally. The fresh thinking and original approach of Redx Anti-Infectives will help create effective solutions to these critical problems. Redx is a discovery engine for global pharma and it is innovative and agile companies like ours that can help the industry adapt to a new model of research and development where there is more willingness to outsource some of the challenges involved in creating new proprietary medicines. At Redx, our methods have already uncovered commercial potential that might otherwise have been missed and our approach helps partners to bring new medicines to market faster.

Whilst our headquarters remain in Liverpool and we have ambitious plans to grow our business and create high value science posts in the city, at the same time we recognise that the facilities at Alderley Park are world class and enable us to move quickly in expanding this key new part of our business. We will be working closely with our colleagues at AstraZeneca, who made a compelling commercial case to attract us to Alderley Park. We look forward to a long and fruitful collaboration.

Clive Morris, AstraZeneca Vice President, Research & Development said: We are delighted to welcome Redx to Alderley Park, which is an important first step in our ambition to secure a sustainable future for the site. We will continue to seek further opportunities to attract other innovation-driven companies and, wherever possible, build on the existing bioscience expertise and world class facilities available at Alderley Park.

Redx has a busy recruitment programme and hopes to take advantage of the high quality workforce in the area. Alderley Park has a long and rich heritage of important advancements in medical treatments developed at the site.

Redx develops therapeutic remedies based on existing classes of drugs, structurally modifying them to create new proprietary medicines. Benefits for patients include fewer side effects, greater efficacy and ease of use for people. The company achieves revenues by entering into licensing agreements with mid-sized and large pharmaceutical partners who undertake further clinical studies with promising new drug compounds.

Redx Anti-Infectives is the third business which has been created by the Redx Pharma group, which was founded in 2010. It follows Redx Oncology, which is also based in Liverpool, and Redx Crop Protection, which operates from Frome, Somerset.

Redx has previously won RGF backing for the launch of its first spin out, Redx Oncology Ltd, a cancer drug research and development subsidiary which currently employs 111 people in Liverpool. The UK Government Business Secretary Vince Cable visited the Redx Oncology laboratories in 2012 to meet staff and see the progress for himself.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Redx Pharma Appoints New Chairman
Company has appointed Dr Frank Armstrong as its non-executive chairman.
Saturday, September 06, 2014
Redx Pharma Agrees Dishman Collaboration
License agreement will allow Dishman to use process technology patented by the Liverpool-based firm.
Tuesday, September 25, 2012
Pioneering Cancer Research Firm Opens in Liverpool
Launch of Redx Oncology, a new cancer research and development company based in Liverpool.
Tuesday, April 03, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!